Richard Schilsky to Administration, Oral
This is a "connection" page, showing publications Richard Schilsky has written about Administration, Oral.
Connection Strength
0.457
-
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer. 2004 Mar 22; 90(6):1190-7.
Score: 0.054
-
Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. J Clin Oncol. 2002 Mar 15; 20(6):1519-26.
Score: 0.047
-
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. J Clin Oncol. 2002 Jan 15; 20(2):582-7.
Score: 0.046
-
Oral fluoropyrimidine treatment of colorectal cancer. Clin Colorectal Cancer. 2001 Aug; 1(2):95-103.
Score: 0.045
-
A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer. Ann Oncol. 2000 Apr; 11(4):415-20.
Score: 0.041
-
The oral fluoropyrimidines in cancer chemotherapy. Clin Cancer Res. 1999 Sep; 5(9):2289-96.
Score: 0.039
-
Biochemical and clinical pharmacology of 5-fluorouracil. Oncology (Williston Park). 1998 Oct; 12(10 Suppl 7):13-8.
Score: 0.037
-
Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062). Clin Cancer Res. 1997 May; 3(5):719-25.
Score: 0.033
-
Clinical pharmacokinetics of high-dose leucovorin calcium after intravenous and oral administration. J Natl Cancer Inst. 1990 Sep 05; 82(17):1411-5.
Score: 0.021
-
Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer. Cancer Chemother Pharmacol. 2007 Nov; 60(6):811-9.
Score: 0.016
-
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. Ann Oncol. 2004 Nov; 15(11):1705-11.
Score: 0.014
-
Phase I study of an oral formulation of ZD9331 administered daily for 28 days. J Clin Oncol. 2003 May 01; 21(9):1859-65.
Score: 0.013
-
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol. 2002 Apr; 13(4):566-75.
Score: 0.012
-
Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma. Cancer. 2001 Apr 01; 91(7):1256-63.
Score: 0.011
-
Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2000 Aug; 18(15):2894-901.
Score: 0.010
-
Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin. Cancer Chemother Pharmacol. 1997; 39(3):227-32.
Score: 0.008
-
Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study. Cancer Chemother Pharmacol. 1993; 32(5):347-52.
Score: 0.006
-
Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer. Semin Oncol. 1992 Jun; 19(3 Suppl 9):53-8.
Score: 0.006